SecBot SecBot

NEUP

Neuphoria Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0001191070 Biotech & Drug Discovery
$3.38 −0.06 (−1.74%)
Oct 26 4:00 PM ET · prev $3.44
Market cap
$18.8M
Nano cap
Median target
$7.00
+107% · range $7.00–7.00
Next earnings
Nov 12
in 17 days
1 year
−25.4%
from $4.53 · Oct 27
30 days
−7.4%
from $3.65
52-week range
$3.24–5.48
−38% from high · low Oct 14
Avg volume 20D
22.8K
Oct 16 spike 76.0K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL AdvisorShares Trust disclosed a passive 5.78% stake in Neuphoria Therapeutics Inc. via Schedule 13G, holding…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    7% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED72,559$317.1K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED52,007$211.7K
UBS Group AGADD2,316$9.4K
GEODE CAPITAL MANAGEMENT, LLCADD17,303$67.1K
RHUMBLINE ADVISERSDOUBLED202$783.00
MORGAN STANLEYDOUBLED58$225.00
BANK OF AMERICA CORP /DE/DOUBLED17$201.00
RHUMBLINE ADVISERSNEAR_EXIT33$234.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +107%.Targets as of May 14, 2026.

Recent actions
DateFirmActionRating
May 15, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral

Earnings setup

Estimates
Nov 12
reports in 17 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$2.43-$2.43–-$2.43+0.0%$0.00
Next FY-$2.46-$2.46–-$2.46+0.0%$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
NEUP Q1 2027 Earnings Scheduled — 2026-11-12
Recent
Sep 28, 2026
Earnings date
NEUP Q4 2026 Earnings Scheduled — 2026-09-28
Jun 26, 2026
M&A
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination
May 18, 2026
Earnings date
NEUP Q3 2026 Earnings Scheduled — 2026-05-18

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
Neuphoria Therapeutics extended the expiration date of its shareholder rights plan (poison pill) by one year, from…
8-K — Impact 2/10
Oct 5, 2026 SEC
AdvisorShares Trust disclosed a passive 5.78% stake in Neuphoria Therapeutics Inc. via Schedule 13G, holding 312,895…
SC 13G — Impact 3/10
Sep 28, 2026 Earnings calendar
NEUP Q4 2026 Earnings Scheduled — 2026-09-28
Sep 18, 2026 SEC
Neuphoria Therapeutics Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026…
DEFA14A — Impact 3/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
72,559 shares ($317.1K)
Jun 26, 2026 Press
Neuphoria Therapeutics confirms it is in preliminary discussions with UK-based Scancell Holdings regarding a potential…
Impact 6/10
Mar 31, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
52,007 shares ($211.7K)

SecBot reports

5 filings · 1 press release · 0 bullish · 0 bearish · 5 neutral
All NEUP filing & press-release reports (6)